Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

By sjmartinez • August 22, 2022

Chew KW, Moser C, Daar ES, Wohl DA, Li JZ, Coombs RW, Ritz J, Giganti M, Javan AC, Li Y, Choudhary MC, Deo R, Malvestutto C, Klekotka P, Price K, Nirula A, Fischer W, Bala V, Ribeiro RM, Perelson AS, Fletcher CV, Eron JJ, Currier JS; ACTIV-2/A5401 Study Team, Hughes MD, Smith DM. Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19. Nat Commun. 2022 Aug 22;13(1):4931. doi: 10.1038/s41467-022-32551-2. PMID: 35995785; PMCID: PMC9395368.

Tags: Infectious Diseases, Publications

Assessment of disability and disease burden in neuromyelitis optica spectrum disorders in the CIRCLES Cohort

Gholizadeh S, Exuzides A, Sinnott J, Palmer C, Waltz M, Rose JW, Jolley AM, Behne JM, Behne MK, Blaschke TF, Smith TJ, Lewis KE, Cook[...]

Preparing better: Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) therapeutics trials lessons learned: A call to the future

Adam SJ, Buchman TG, Currier JS, Draghia-Akli R, Fessel JP, Higgs ES, Hughes EA, LaVange L, Menetski JP, Read SW, Rosenberg Y, Tressler R; ACTIV[...]

ACTIV trials: Lessons learned in trial design in the setting of an emergent pandemic

Keshtkar-Jahromi M, Anstrom KJ, Barkauskas C, Brown SM, Daar ES, Fischer W, Gibbs KW, Higgs ES, Hughes MD, Jagannathan P, LaVange L, Lindsell CJ, Nayak[...]